$16.34
-0.70 (-4.11%)
Open$17.00
Previous Close$17.04
Day High$17.01
Day Low$16.32
52W High$34.19
52W Low$13.96
Volume—
Avg Volume356.8K
Market Cap825.95M
P/E Ratio—
EPS$-2.07
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.70M | 9.1K | 117.17M |
| Net Income | -65,694,840 | -50,362 | -10,038,830 |
| Profit Margin | -980.9% | -582.6% | -8.6% |
| EBITDA | -74,580,847 | -48,936 | -16,056,956 |
| Free Cash Flow | — | — | -11,744,338 |
| Rev Growth | +147.5% | +60.5% | +1.7% |
| Debt/Equity | — | 0.51 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |